Canada launching huge prospective cancer study

Canadian researchers have announced the launch of an enormous prospective study that they believe will provide tremendous insight into the causes of cancer and other chronic diseases among the Canadian population. They believe that the data collected will provide the foundation for hundreds of associated studies in years to come, and they also feel that this effort is unique, in part because it will focus on environmental risk factors for cancers and other diseases.

According to Marilyn J. Borugian, PhD, of the Cancer Control Research Program of the British Columbia Cancer Agency, this study "will form the foundation for a major research platform for the study of disease causation, both nationally and internationally."

COHORT

Researchers aim to enroll patients between the ages of 35 and 69 from across Canada, and to follow them for a minimum of 25 years. Enrollment has already gotten underway and is expected to be complete by 2012.

PUBLICATIONS

The project was announced online in the Canadian Medical Association Journal. Majority funding will come from the Canadian Partnership Against Cancer.

By Ross Bonander

Source: Press Release

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap